Partner Orphan

Times have changed and the majority of new drug developments are now emerging from start-ups to small sized pharma/biotech firms. This is great news! however, the core teams within these organisations are often small and outsourcing becomes a key requirement. With two decades of experience, Partner Orphan can advise and manage your rare disorders activities with a true understanding of requirements. Our extensive experience enables us to navigate strategically and support either your drug development, or post MA plans to fruition. From stakeholder management. early access to medicines advisory, through to UK market access strategies and troubleshooting implementation; rare is what we do. We are passionate and endeavour to bring results above your expectation.